Corneal Neovascularization Clinical Trial
Official title:
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of Conbercept Eye Drops in Patients With Corneal Neovascularization
The first stage of this study will evaluates the tolerability of different concentrations of
Conbercept eye drop to patients with corneal neovascularization.
The second stage of this study will evaluate the effectiveness of conbercept eye drop
initially.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00555594 -
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
|
Phase 2/Phase 3 | |
| Completed |
NCT00004430 -
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
|
N/A | |
| Completed |
NCT00769145 -
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
|
Phase 1 | |
| Completed |
NCT01257750 -
Treatment of Corneal Neovascularization With Topical Pazopanib
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04787471 -
Corneal Crosslinking for Treatment of Corneal Neovascularization
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
| Active, not recruiting |
NCT00992849 -
Bevacizumab for the Treatment of Corneal Neovascularization
|
Phase 2 | |
| Withdrawn |
NCT00515684 -
Corneal Thinning During Topical Bevacizumab Therapy
|
N/A | |
| Terminated |
NCT02797704 -
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
| Terminated |
NCT01868360 -
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
|
Phase 1 | |
| Withdrawn |
NCT02042027 -
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
|
Phase 1 | |
| Completed |
NCT00797303 -
The Effect of Bevacizumab on Corneal Neovascularization
|
Phase 4 | |
| Recruiting |
NCT05659940 -
Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
|
||
| Completed |
NCT00559936 -
Topical Avastin for Treatment of Corneal Neovascularization
|
Phase 1 | |
| Completed |
NCT01072357 -
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04620109 -
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
|
Phase 1 | |
| Completed |
NCT00512876 -
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
|
N/A | |
| Recruiting |
NCT05011916 -
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
| Completed |
NCT01996826 -
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
| Terminated |
NCT00915590 -
Topical IL-1-Ra for Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 |